Dmour Bianca-Ana, Costache Alexandru Dan, Dmour Awad, Huzum Bogdan, Duca Ștefania Teodora, Chetran Adriana, Miftode Radu Ștefan, Afrăsânie Irina, Tuchiluș Cristina, Cianga Corina Maria, Botnariu Gina, Șerban Lăcrămioara Ionela, Ciocoiu Manuela, Bădescu Codruța Minerva, Costache Irina Iuliana
Department of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
Department of Cardiovascular Rehabilitation, Clinical Rehabilitation Hospital, 700661 Iași, Romania.
Diagnostics (Basel). 2023 Jul 5;13(13):2277. doi: 10.3390/diagnostics13132277.
Acute heart failure (AHF) is a life-threatening condition with high morbidity and mortality. Even though this pathology has been extensively researched, there are still challenges in establishing an accurate and early diagnosis, determining the long- and short-term prognosis and choosing a targeted therapeutic strategy. The use of reliable biomarkers to support clinical judgment has been shown to improve the management of AHF patients. Despite a large pool of interesting candidate biomarkers, endothelin-1 (ET-1) appears to be involved in multiple aspects of AHF pathogenesis that include neurohormonal activation, cardiac remodeling, endothelial dysfunction, inflammation, atherosclerosis and alteration of the renal function. Since its discovery, numerous studies have shown that the level of ET-1 is associated with the severity of symptoms and cardiac dysfunction in this pathology. The purpose of this paper is to review the existing information on ET-1 and answer the question of whether this neurohormone could be a promising biomarker in AHF.
急性心力衰竭（AHF）是一种危及生命的疾病，发病率和死亡率都很高。尽管对这种病理状况已进行了广泛研究，但在建立准确的早期诊断、确定长期和短期预后以及选择有针对性的治疗策略方面仍存在挑战。使用可靠的生物标志物来支持临床判断已被证明可改善AHF患者的管理。尽管有大量有趣的候选生物标志物，但内皮素-1（ET-1）似乎参与了AHF发病机制的多个方面，包括神经激素激活、心脏重塑、内皮功能障碍、炎症、动脉粥样硬化和肾功能改变。自发现以来，大量研究表明，在这种病理状况下，ET-1水平与症状严重程度和心脏功能障碍相关。本文的目的是回顾关于ET-1的现有信息，并回答这种神经激素是否可能成为AHF中有前景的生物标志物这一问题。
